These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 12407586)

  • 21. [Retreatment for patients with chronic hepatitis B relapse after initial antiviral therapy].
    Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jun; 19(6):405-7. PubMed ID: 22053366
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy of early retreatment with interferon beta for relapse in patients with genotype Ib chronic hepatitis C.
    Nomura H; Sou S; Nagahama T; Hayashi J; Kashiwagi S; Ishibashi H
    Hepatol Res; 2004 Jan; 28(1):36-40. PubMed ID: 14734149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Letter: retreatment of patients with chronic hepatitis C who have failed interferon-free combination therapy with direct acting anti-virals.
    Kozbial K; Aberle SW; Susser S; Al-Zoairy R; Moser S; Stättermayer AF; Maieron A; Gschwantler M; Stauber R; Graziadei I; Zoller H; Beinhardt S; Holzmann H; Munda-Steindl P; Hofer H; Sarrazin C; Ferenci P
    Aliment Pharmacol Ther; 2017 Jan; 45(2):373-375. PubMed ID: 27910121
    [No Abstract]   [Full Text] [Related]  

  • 24. The new standard of HCV therapy: Retreatment in experienced patients.
    Gara N; Ghany MG
    Clin Liver Dis (Hoboken); 2012 Feb; 1(1):16-19. PubMed ID: 31186839
    [No Abstract]   [Full Text] [Related]  

  • 25. Inhalational therapy, advances and retreats.
    BARACH AL
    Anesthesiology; 1961; 22():367-78. PubMed ID: 13686670
    [No Abstract]   [Full Text] [Related]  

  • 26. Life After Medicine: A Time to Smell the Roses.
    Bogart DB
    Mo Med; 2016; 113(3):176-7. PubMed ID: 27443040
    [No Abstract]   [Full Text] [Related]  

  • 27. Advances in the Treatment of Hepatitis B and Hepatitis C Nonresponders: A Report of Symposia Presented at the 15th Conference of the Asian Pacific Association for the Study of the LiverAugust 18-21, 2005Bali, Indonesia.
    Gastroenterol Hepatol (N Y); 2006 Jan; 2(1 Suppl 1):1-16. PubMed ID: 28852373
    [No Abstract]   [Full Text] [Related]  

  • 28. Consensus interferon plus ribavirin for hepatitis C genotype 3 patients previously treated with pegylated interferon plus ribavirin.
    Abbas Z; Tayyab GN; Qureshi M; Memon MS; Subhan A; Shakir T; Jafri W; Hamid S
    Hepat Mon; 2013; 13(12):e14146. PubMed ID: 24358041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.
    Hassanein T; Shiffman ML; Zein NN
    Gastroenterol Hepatol (N Y); 2007 Jun; 3(6 Suppl 20):4-32. PubMed ID: 23329897
    [No Abstract]   [Full Text] [Related]  

  • 30. The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil.
    Artico S; Amaral KM; Gonçalves CB; Picon PD
    BMC Infect Dis; 2012 Dec; 12():377. PubMed ID: 23270376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin.
    Fujino T; Nakamuta M; Aoyagi Y; Kohjima M; Satoh T; Fukuda M; Ishibashi H; Yatsuhashi H; Enjoji M
    Med Sci Monit; 2011 Dec; 17(12):CR687-91. PubMed ID: 22129899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolution of interferon-based therapy for chronic hepatitis C.
    Chen CH; Yu ML
    Hepat Res Treat; 2010; 2010():140953. PubMed ID: 21152178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
    Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
    Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonresponse to treatment for hepatitis C: current management strategies.
    Yuan HJ; Lee WM
    Drugs; 2008; 68(1):27-42. PubMed ID: 18081371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C.
    Gramenzi A; Andreone P; Cursaro C; Verucchi G; Boccia S; Giacomoni PL; Galli S; Furlini G; Biselli M; Lorenzini S; Attard L; Bonvicini F; Bernardi M
    J Gastroenterol; 2007 May; 42(5):362-7. PubMed ID: 17530360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.
    Sherman M; Yoshida EM; Deschenes M; Krajden M; Bain VG; Peltekian K; Anderson F; Kaita K; Simonyi S; Balshaw R; Lee SS;
    Gut; 2006 Nov; 55(11):1631-8. PubMed ID: 16709661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.
    Younossi ZM; McCullough AC; Barnes DS; Post A; Ong JP; O'Shea R; Martin LM; Bringman D; Farmer D; Levinthal G; Mullen KD; Carey WD; Tavill AS; Ferguson R; Gramlich T
    Dig Dis Sci; 2005 May; 50(5):970-5. PubMed ID: 15906777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonresponders to Previous Chronic Hepatitis C Treatment.
    Gross JB
    Curr Treat Options Gastroenterol; 2004 Dec; 7(6):469-475. PubMed ID: 15527713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine.
    Stauber RE; Hofer H; Hackl F; Schütze K; Datz C; Hegenbarth K; Jessner W; Steindl-Munda P; Peter F;
    Wien Klin Wochenschr; 2004 Aug; 116(15-16):530-5. PubMed ID: 15471180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hematopoietic growth factors for acute myelogenous leukemia.
    Kalaycio M
    Curr Hematol Rep; 2004 Jan; 3(1):38-9. PubMed ID: 14695848
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.